198 related articles for article (PubMed ID: 35933242)
1. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
de Ruiter BM; van Hattum JW; Lipman D; de Reijke TM; van Moorselaar RJA; van Gennep EJ; Maartje Piet AH; Donker M; van der Hulle T; Voortman J; Oddens JR; Hulshof MCCM; Bins AD
Eur Urol; 2022 Nov; 82(5):518-526. PubMed ID: 35933242
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P; Siefker-Radtke A; de Braud F; Basso U; Calvo E; Bono P; Morse MA; Ascierto PA; Lopez-Martin J; Brossart P; Rohrberg K; Mellado B; Fischer BS; Meadows-Shropshire S; Abdel Saci ; Callahan MK; Rosenberg J
J Clin Oncol; 2019 Jul; 37(19):1608-1616. PubMed ID: 31100038
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Omuro A; Vlahovic G; Lim M; Sahebjam S; Baehring J; Cloughesy T; Voloschin A; Ramkissoon SH; Ligon KL; Latek R; Zwirtes R; Strauss L; Paliwal P; Harbison CT; Reardon DA; Sampson JH
Neuro Oncol; 2018 Apr; 20(5):674-686. PubMed ID: 29106665
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E; Hussain SA; Porta N; Lewis R; Crundwell M; Jenkins P; Rawlings C; Tremlett J; Sreenivasan T; Wallace J; Syndikus I; Sheehan D; Lydon A; Huddart R; James N;
Eur Urol; 2022 Sep; 82(3):273-279. PubMed ID: 35577644
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
de Ruiter BM; van de Kamp MW; van Steenbergen JPZ; Franckena M; Boormans JL; de Feijter JM; Bins AD; Hulshof MCCM; de Reijke TM; Schaake E; Oddens JR
Eur Urol Open Sci; 2022 May; 39():7-13. PubMed ID: 35528785
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
10. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38155060
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Weickhardt A; Foroudi F; Lawrentschuk N; Xie J; Sidhom M; Pal A; Grimison P; Zhang A; Ng S; Tang C; Hovey E; Chen C; Hruby G; Guminski A; McJannett M; Conduit C; Tran B; Davis ID; Hayne D
Eur Urol Oncol; 2024 Jun; 7(3):469-477. PubMed ID: 37806844
[TBL] [Abstract][Full Text] [Related]
12. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS; van de Kamp MW; Schuring N; Mertens LS; Noordzij A; Pos F; van Rhijn BWG; van der Heijden MS; Schaake EE
Radiother Oncol; 2020 Sep; 150():275-280. PubMed ID: 32768507
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
14. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
Reichert C; Baldini C; Mezghani S; Maubec E; Longvert C; Mortier L; Quereux G; Jannic A; Machet L; de Quatrebarbes J; Nardin C; Beneton N; Amini Adle M; Funck-Brentano E; Descamps V; Hachon L; Malissen N; Baroudjian B; Brunet-Possenti F;
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686606
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Tolerability, Response and Complications of Concurrent Chemoradiation With Capecitabine and Cisplatin in Muscle-Invasive Bladder Cancer; A Single Arm Study.
Soltanzadeh S; Saeedian A; Ghalehtaki R; Ayati M; Nowroozi M; Haddad P; Sabet MS; Kheirolahi A
Clin Genitourin Cancer; 2023 Feb; 21(1):105.e1-105.e6. PubMed ID: 35948483
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
[TBL] [Abstract][Full Text] [Related]
19. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]